4th iPSC Drug Development & Manufacturing Summit 2024
The 4th iPSC Drug Development & Manufacturing Summit is the longest standing and definitive iPSC focused industry platform showcasing cutting-edge advances across R&D through to manufacturing and analytical development to help you stay at the forefront of the iPSC cell therapy revolution.
Date: October 1-3, 2024
Location: The Colonnade, Boston, MA
JOIN US!
Network with top experts and industry leaders to advance your iPSC development pipeline. Learn about the iPSC capabilities at Catalent .
With content split across Research & Development and Manufacturing & Analytical Development tracks, this is the one-stop shop meeting for drug developers and academic thought leaders looking to streamline their route to the clinic and scale up their manufacturing processes.
Complete the form to schedule a meeting with Catalent Cell Therapy experts at the 4th iPSC Drug Development & Manufacturing Summit 2024!
FEATURED SPEAKING SESSION
Title: From Bench To Patient Cure: Unlocking Ipsc Potential Through Innovative Science And Strategic Partnerships
Date: October 2, 2024
Time: 10:00-10:30 am EDT
SPEAKERS
Daniel Terheyden-Keighley Ph.D.
Senior Director
Scientist R&D Department, iPSC/CT
Catalent Cell Therapy
Frederic Cedrone, Ph.D.
Vice President
Corporate Innovation
Catalent
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.
